Description
The first, potent, selective, and orally bioavailable pan With-No-Lysine (WNK) Kinase catalytic activity inhibitor with IC50 of 5/1/6/9nM for WNK1/2/3/4, respectively; shows >50% inhibition against only 2 out of 442 human kinases at 10uM; affects blood pressure and body fluid and electro-lyte homeostasis in rodent models of hypertension